{"entity":{"id":"etx-929","kind":"drug","name":"ETX-929","aka":[],"tldr":"ETX-929 is an experimental small molecule from Ensem Therapeutics, in phase 1 trials for metastatic colorectal cancer, pancreatic ductal adenocarcinoma and non-squamous non-small cell lung cancer and other cancers.","summary":"ETX-929 is a small molecule (oral capsule) from Ensem Therapeutics. An oral pan-KRAS inhibitor that spares HRAS and NRAS and inhibits both the GTP (on) and GDP (off) states, for KRAS-mutant (G12X/G13X/Q61H) and wild-type amplified tumours. Its furthest stage is phase 1, for metastatic colorectal cancer, pancreatic ductal adenocarcinoma, non-squamous non-small cell lung cancer and endometrial adenocarcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07912593 (Ensem sponsor), recruiting, actual start 22 Oct 2026, alone and with cetuximab. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Ensem Therapeutics: ensemtx.com","url":"https://ensemtx.com/science/pipeline/"},{"label":"Ensem Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07912593"},{"label":"ClinicalTrials.gov: trials of ETX-929","url":"https://clinicaltrials.gov/search?intr=ETX-929"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal","pancreatic","nsclc","endometrial","ovarian"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":["ensem-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07912593"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ETX-929","modality":"Small molecule (oral capsule)","mechanism":"An oral pan-KRAS inhibitor that spares HRAS and NRAS and inhibits both the GTP (on) and GDP (off) states, for KRAS-mutant (G12X/G13X/Q61H) and wild-type amplified tumours.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/etx-929/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"ensem-therapeutics","kind":"company","name":"Ensem Therapeutics","route":"/companies/ensem-therapeutics/"}],"trial":[{"id":"nct07912593","kind":"trial","name":"Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct07912593/"}]}}